$TEVA Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in TEVA PHARMACEUTICAL INDUSTRIES LTD.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in TEVA PHARMACEUTICAL INDUSTRIES LTD. Get notifications about new insider transactions in TEVA PHARMACEUTICAL INDUSTRIES LTD for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 16 2021 | TEVA | TEVA PHARMACEUTICA ... | LIEBERMAN GERALD M | Director | Option Exercise | A | 0.00 | 14,479 | 0 | 14,479 | |
Jun 16 2021 | TEVA | TEVA PHARMACEUTICA ... | Hussain Abbas | Director | Option Exercise | A | 0.00 | 14,479 | 0 | 14,479 | |
Jun 16 2021 | TEVA | TEVA PHARMACEUTICA ... | Halfon Jean Michel | Director | Option Exercise | A | 0.00 | 14,479 | 0 | 14,479 | |
Jun 16 2021 | TEVA | TEVA PHARMACEUTICA ... | Elstein Amir | Director | Option Exercise | A | 0.00 | 14,479 | 0 | 14,479 | |
Jun 10 2021 | TEVA | TEVA PHARMACEUTICA ... | Peres Nechemia Jacob | Director | Option Exercise | M | 0.00 | 12,668 | 0 | 0 | |
Jun 10 2021 | TEVA | TEVA PHARMACEUTICA ... | Peres Nechemia Jacob | Director | Buy | M | 0.00 | 12,668 | 0 | 44,286 | 31.6 K to 44.3 K (+40.07 %) |
Jun 10 2021 | TEVA | TEVA PHARMACEUTICA ... | Vergis Janet S. | Director | Option Exercise | M | 0.00 | 12,668 | 0 | 0 | |
Jun 10 2021 | TEVA | TEVA PHARMACEUTICA ... | Vergis Janet S. | Director | Buy | M | 0.00 | 12,668 | 0 | 12,668 | 0 to 12.7 K |
Jun 10 2021 | TEVA | TEVA PHARMACEUTICA ... | Satchi-Fainaro Ronit | Director | Option Exercise | M | 0.00 | 12,668 | 0 | 0 | |
Jun 10 2021 | TEVA | TEVA PHARMACEUTICA ... | Satchi-Fainaro Ronit | Director | Buy | M | 0.00 | 12,668 | 0 | 36,330 | 23.7 K to 36.3 K (+53.54 %) |
Jun 10 2021 | TEVA | TEVA PHARMACEUTICA ... | Elstein Amir | Director | Option Exercise | M | 0.00 | 12,668 | 0 | 0 | |
Jun 10 2021 | TEVA | TEVA PHARMACEUTICA ... | Elstein Amir | Director | Buy | M | 0.00 | 12,668 | 0 | 2,042,934 | 2 M to 2 M (+0.62 %) |
Jun 10 2021 | TEVA | TEVA PHARMACEUTICA ... | Crane Rosemary A | Director | Option Exercise | M | 0.00 | 12,668 | 0 | 0 | |
Jun 10 2021 | TEVA | TEVA PHARMACEUTICA ... | Crane Rosemary A | Director | Buy | M | 0.00 | 12,668 | 0 | 52,218 | 39.6 K to 52.2 K (+32.03 %) |
Jun 08 2021 | TEVA | TEVA PHARMACEUTICA ... | Satchi-Fainaro Ronit | Director | Option Exercise | M | 0.00 | 6,041 | 0 | 0 | |
Jun 08 2021 | TEVA | TEVA PHARMACEUTICA ... | Satchi-Fainaro Ronit | Director | Buy | M | 0.00 | 6,041 | 0 | 23,662 | 17.6 K to 23.7 K (+34.28 %) |
Jun 08 2021 | TEVA | TEVA PHARMACEUTICA ... | Peres Nechemia Jacob | Director | Option Exercise | M | 0.00 | 6,041 | 0 | 0 | |
Jun 08 2021 | TEVA | TEVA PHARMACEUTICA ... | Peres Nechemia Jacob | Director | Buy | M | 0.00 | 6,041 | 0 | 31,618 | 25.6 K to 31.6 K (+23.62 %) |
May 25 2021 | TEVA | TEVA PHARMACEUTICA ... | Drape Eric | Executive VP Global ... | Sell | S | 11.01 | 40,000 | 440,320 | 33,128 | 73.1 K to 33.1 K (-54.70 %) |
May 13 2021 | TEVA | TEVA PHARMACEUTICA ... | Stark David Matthew | Exec. VP Chief Lega ... | Option Exercise | M | 0.00 | 37,884 | 0 | 0 | |
May 13 2021 | TEVA | TEVA PHARMACEUTICA ... | Stark David Matthew | Exec. VP Chief Lega ... | Sell | S | 10.22 | 37,884 | 387,125 | 2,974 | 40.9 K to 3 K (-92.72 %) |
May 13 2021 | TEVA | TEVA PHARMACEUTICA ... | Stark David Matthew | Exec. VP Chief Lega ... | Buy | M | 0.00 | 37,884 | 0 | 40,858 | 3 K to 40.9 K (+1,273.84 %) |
May 13 2021 | TEVA | TEVA PHARMACEUTICA ... | Sabag Mark | See "Remarks" below | Option Exercise | M | 0.00 | 37,884 | 0 | 0 | |
May 13 2021 | TEVA | TEVA PHARMACEUTICA ... | Sabag Mark | See "Remarks" below | Buy | M | 0.00 | 37,884 | 0 | 58,482 | 20.6 K to 58.5 K (+183.92 %) |
May 13 2021 | TEVA | TEVA PHARMACEUTICA ... | Fridriksdottir Hafrun | Executive VP, Globa ... | Option Exercise | M | 0.00 | 37,884 | 0 | 0 | |
May 13 2021 | TEVA | TEVA PHARMACEUTICA ... | Fridriksdottir Hafrun | Executive VP, Globa ... | Sell | S | 10.22 | 19,066 | 194,830 | 92,272 | 111.3 K to 92.3 K (-17.12 %) |
May 13 2021 | TEVA | TEVA PHARMACEUTICA ... | Fridriksdottir Hafrun | Executive VP, Globa ... | Buy | M | 0.00 | 37,884 | 0 | 111,338 | 73.5 K to 111.3 K (+51.58 %) |
May 13 2021 | TEVA | TEVA PHARMACEUTICA ... | Drape Eric | Executive VP Global ... | Option Exercise | M | 0.00 | 37,884 | 0 | 0 | |
May 13 2021 | TEVA | TEVA PHARMACEUTICA ... | Drape Eric | Executive VP Global ... | Sell | S | 10.22 | 19,804 | 202,413 | 73,128 | 92.9 K to 73.1 K (-21.31 %) |
May 13 2021 | TEVA | TEVA PHARMACEUTICA ... | Drape Eric | Executive VP Global ... | Buy | M | 0.00 | 37,884 | 0 | 92,932 | 55 K to 92.9 K (+68.82 %) |
Mar 17 2021 | TEVA | TEVA PHARMACEUTICA ... | Sabag Mark | See "Remarks" below | Sell | S | 11.22 | 127,244 | 1,427,614 | 20,598 | 147.8 K to 20.6 K (-86.07 %) |
Mar 08 2021 | TEVA | TEVA PHARMACEUTICA ... | Stark David Matthew | Exec. VP Chief Lega ... | Option Exercise | A | 0.00 | 80,798 | 0 | 80,798 | |
Mar 08 2021 | TEVA | TEVA PHARMACEUTICA ... | Stark David Matthew | Exec. VP Chief Lega ... | Option Exercise | M | 0.00 | 13,930 | 0 | 27,861 | |
Mar 08 2021 | TEVA | TEVA PHARMACEUTICA ... | Stark David Matthew | Exec. VP Chief Lega ... | Sell | S | 10.57 | 13,930 | 147,186 | 2,974 | 16.9 K to 3 K (-82.41 %) |
Mar 08 2021 | TEVA | TEVA PHARMACEUTICA ... | Stark David Matthew | Exec. VP Chief Lega ... | Buy | M | 0.00 | 13,930 | 0 | 16,904 | 3 K to 16.9 K (+468.39 %) |
Mar 08 2021 | TEVA | TEVA PHARMACEUTICA ... | Schultz Kare | President and CEO | Option Exercise | A | 0.00 | 285,171 | 0 | 285,171 | |
Mar 08 2021 | TEVA | TEVA PHARMACEUTICA ... | Schultz Kare | President and CEO | Option Exercise | M | 0.00 | 59,701 | 0 | 119,403 | |
Mar 08 2021 | TEVA | TEVA PHARMACEUTICA ... | Schultz Kare | President and CEO | Buy | M | 0.00 | 59,701 | 0 | 860,582 | 800.9 K to 860.6 K (+7.45 %) |
Mar 08 2021 | TEVA | TEVA PHARMACEUTICA ... | Sabag Mark | See "Remarks" below | Option Exercise | A | 0.00 | 95,057 | 0 | 95,057 | |
Mar 08 2021 | TEVA | TEVA PHARMACEUTICA ... | Sabag Mark | See "Remarks" below | Option Exercise | M | 0.00 | 15,920 | 0 | 31,841 | |
Mar 08 2021 | TEVA | TEVA PHARMACEUTICA ... | Sabag Mark | See "Remarks" below | Buy | M | 0.00 | 15,920 | 0 | 147,842 | 131.9 K to 147.8 K (+12.07 %) |
Mar 08 2021 | TEVA | TEVA PHARMACEUTICA ... | Nazzi Gianfranco | EVP, International ... | Option Exercise | M | 0.00 | 12,935 | 0 | 25,870 | |
Mar 08 2021 | TEVA | TEVA PHARMACEUTICA ... | Nazzi Gianfranco | EVP, International ... | Sell | S | 10.58 | 12,935 | 136,909 | 0 | 12.9 K to 0 (-100.00 %) |
Mar 08 2021 | TEVA | TEVA PHARMACEUTICA ... | Nazzi Gianfranco | EVP, International ... | Grant | A | 0.00 | 12,935 | 0 | 12,935 | 0 to 12.9 K |
Mar 08 2021 | TEVA | TEVA PHARMACEUTICA ... | Kalif Eliyahu Sharon | EVP, Chief Financia ... | Option Exercise | A | 0.00 | 85,551 | 0 | 85,551 | |
Mar 08 2021 | TEVA | TEVA PHARMACEUTICA ... | Fridriksdottir Hafrun | Executive VP, Globa ... | Option Exercise | A | 0.00 | 95,057 | 0 | 95,057 | |
Mar 08 2021 | TEVA | TEVA PHARMACEUTICA ... | Fridriksdottir Hafrun | Executive VP, Globa ... | Option Exercise | M | 0.00 | 18,905 | 0 | 37,811 | |
Mar 08 2021 | TEVA | TEVA PHARMACEUTICA ... | Fridriksdottir Hafrun | Executive VP, Globa ... | Sell | S | 10.57 | 9,515 | 100,536 | 73,454 | 83 K to 73.5 K (-11.47 %) |
Mar 08 2021 | TEVA | TEVA PHARMACEUTICA ... | Fridriksdottir Hafrun | Executive VP, Globa ... | Buy | M | 0.00 | 18,905 | 0 | 82,969 | 64.1 K to 83 K (+29.51 %) |
Mar 08 2021 | TEVA | TEVA PHARMACEUTICA ... | Drape Eric | Executive VP Global ... | Option Exercise | A | 0.00 | 90,304 | 0 | 90,304 | |
Mar 08 2021 | TEVA | TEVA PHARMACEUTICA ... | Drape Eric | Executive VP Global ... | Option Exercise | M | 0.00 | 11,940 | 0 | 23,880 | |
Mar 08 2021 | TEVA | TEVA PHARMACEUTICA ... | Drape Eric | Executive VP Global ... | Sell | S | 10.58 | 6,183 | 65,443 | 55,048 | 61.2 K to 55 K (-10.10 %) |
Mar 08 2021 | TEVA | TEVA PHARMACEUTICA ... | Drape Eric | Executive VP Global ... | Buy | M | 0.00 | 11,940 | 0 | 61,231 | 49.3 K to 61.2 K (+24.22 %) |
Mar 08 2021 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Option Exercise | A | 0.00 | 99,809 | 0 | 99,809 | |
Mar 08 2021 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Option Exercise | M | 0.00 | 13,930 | 0 | 27,861 | |
Mar 08 2021 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Sell | S | 10.57 | 6,012 | 63,523 | 77,976 | 84 K to 78 K (-7.16 %) |
Mar 08 2021 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Buy | M | 0.00 | 13,930 | 0 | 83,988 | 70.1 K to 84 K (+19.88 %) |
Mar 08 2021 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Option Exercise | A | 0.00 | 90,304 | 0 | 90,304 | |
Mar 08 2021 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Option Exercise | M | 0.00 | 15,920 | 0 | 31,841 | |
Mar 08 2021 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Sell | S | 10.58 | 7,513 | 79,521 | 20,280 | 27.8 K to 20.3 K (-27.03 %) |
Mar 08 2021 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Buy | M | 0.00 | 15,920 | 0 | 27,793 | 11.9 K to 27.8 K (+134.09 %) |
Mar 04 2021 | TEVA | TEVA PHARMACEUTICA ... | Nazzi Gianfranco | EVP, International ... | Option Exercise | M | 0.00 | 1,400 | 0 | 0 | |
Mar 04 2021 | TEVA | TEVA PHARMACEUTICA ... | Nazzi Gianfranco | EVP, International ... | Sell | S | 10.88 | 1,400 | 15,231 | 0 | 1.4 K to 0 (-100.00 %) |
Mar 04 2021 | TEVA | TEVA PHARMACEUTICA ... | Nazzi Gianfranco | EVP, International ... | Buy | M | 0.00 | 1,400 | 0 | 1,400 | 0 to 1.4 K |
Mar 04 2021 | TEVA | TEVA PHARMACEUTICA ... | Fridriksdottir Hafrun | Executive VP, Globa ... | Sell | S | 10.82 | 50,000 | 540,890 | 64,064 | 114.1 K to 64.1 K (-43.84 %) |
Mar 04 2021 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Option Exercise | M | 0.00 | 1,400 | 0 | 0 | |
Mar 04 2021 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Sell | S | 10.86 | 606 | 6,583 | 70,058 | 70.7 K to 70.1 K (-0.86 %) |
Mar 04 2021 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Buy | M | 0.00 | 1,400 | 0 | 70,664 | 69.3 K to 70.7 K (+2.02 %) |
Mar 04 2021 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Option Exercise | M | 0.00 | 2,101 | 0 | 0 | |
Mar 04 2021 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Sell | S | 10.88 | 993 | 10,803 | 11,873 | 12.9 K to 11.9 K (-7.72 %) |
Mar 04 2021 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Buy | M | 0.00 | 2,101 | 0 | 12,866 | 10.8 K to 12.9 K (+19.52 %) |
Mar 02 2021 | TEVA | TEVA PHARMACEUTICA ... | Schultz Kare | President and CEO | Option Exercise | M | 0.00 | 65,047 | 0 | 195,143 | |
Mar 02 2021 | TEVA | TEVA PHARMACEUTICA ... | Schultz Kare | President and CEO | Buy | M | 0.00 | 65,047 | 0 | 800,881 | 735.8 K to 800.9 K (+8.84 %) |
Mar 02 2021 | TEVA | TEVA PHARMACEUTICA ... | Sabag Mark | See "Remarks" below | Option Exercise | M | 0.00 | 20,598 | 0 | 61,795 | |
Mar 02 2021 | TEVA | TEVA PHARMACEUTICA ... | Sabag Mark | See "Remarks" below | Buy | M | 0.00 | 20,598 | 0 | 131,922 | 111.3 K to 131.9 K (+18.50 %) |
Mar 02 2021 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Option Exercise | M | 0.00 | 24,934 | 0 | 74,805 | |
Mar 02 2021 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Sell | S | 10.93 | 63,278 | 691,350 | 29,953 | 93.2 K to 30 K (-67.87 %) |
Mar 02 2021 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Sell | S | 10.83 | 9,849 | 106,673 | 93,231 | 103.1 K to 93.2 K (-9.55 %) |
Mar 02 2021 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Buy | M | 0.00 | 24,934 | 0 | 103,080 | 78.1 K to 103.1 K (+31.91 %) |
Mar 02 2021 | TEVA | TEVA PHARMACEUTICA ... | Nazzi Gianfranco | EVP, International ... | Option Exercise | M | 0.00 | 15,177 | 0 | 45,534 | |
Mar 02 2021 | TEVA | TEVA PHARMACEUTICA ... | Nazzi Gianfranco | EVP, International ... | Sell | S | 10.88 | 60,410 | 657,237 | 0 | 60.4 K to 0 (-100.00 %) |
Mar 02 2021 | TEVA | TEVA PHARMACEUTICA ... | Nazzi Gianfranco | EVP, International ... | Sell | S | 10.85 | 15,177 | 164,684 | 60,410 | 75.6 K to 60.4 K (-20.08 %) |
Mar 02 2021 | TEVA | TEVA PHARMACEUTICA ... | Nazzi Gianfranco | EVP, International ... | Buy | M | 0.00 | 15,177 | 0 | 75,587 | 60.4 K to 75.6 K (+25.12 %) |
Mar 02 2021 | TEVA | TEVA PHARMACEUTICA ... | Kalif Eliyahu Sharon | EVP, Chief Financia ... | Option Exercise | M | 0.00 | 18,430 | 0 | 55,290 | |
Mar 02 2021 | TEVA | TEVA PHARMACEUTICA ... | Kalif Eliyahu Sharon | EVP, Chief Financia ... | Buy | M | 0.00 | 18,430 | 0 | 18,430 | 0 to 18.4 K |
Mar 02 2021 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Option Exercise | M | 0.00 | 17,346 | 0 | 52,038 | |
Mar 02 2021 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Sell | S | 10.83 | 7,486 | 81,079 | 69,264 | 76.8 K to 69.3 K (-9.75 %) |
Mar 02 2021 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Buy | M | 0.00 | 17,346 | 0 | 76,750 | 59.4 K to 76.8 K (+29.20 %) |
Mar 02 2021 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Option Exercise | M | 0.00 | 20,598 | 0 | 61,795 | |
Mar 02 2021 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Sell | S | 10.85 | 20,598 | 223,507 | 10,765 | 31.4 K to 10.8 K (-65.68 %) |
Mar 02 2021 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Buy | M | 0.00 | 20,598 | 0 | 31,363 | 10.8 K to 31.4 K (+191.34 %) |
Feb 17 2021 | TEVA | TEVA PHARMACEUTICA ... | Sabag Mark | See "Remarks" below | Option Exercise | M | 0.00 | 5,712 | 0 | 0 | |
Feb 17 2021 | TEVA | TEVA PHARMACEUTICA ... | Sabag Mark | See "Remarks" below | Buy | M | 0.00 | 5,712 | 0 | 111,324 | 105.6 K to 111.3 K (+5.41 %) |
Feb 17 2021 | TEVA | TEVA PHARMACEUTICA ... | Fridriksdottir Hafrun | Executive VP, Globa ... | Option Exercise | M | 0.00 | 5,355 | 0 | 0 | |
Feb 17 2021 | TEVA | TEVA PHARMACEUTICA ... | Fridriksdottir Hafrun | Executive VP, Globa ... | Sell | S | 11.12 | 2,098 | 23,336 | 103,294 | 105.4 K to 103.3 K (-1.99 %) |
Feb 17 2021 | TEVA | TEVA PHARMACEUTICA ... | Fridriksdottir Hafrun | Executive VP, Globa ... | Buy | M | 0.00 | 5,355 | 0 | 105,392 | 100 K to 105.4 K (+5.35 %) |
Feb 17 2021 | TEVA | TEVA PHARMACEUTICA ... | Drape Eric | Executive VP Global ... | Option Exercise | M | 0.00 | 3,926 | 0 | 0 | |
Feb 17 2021 | TEVA | TEVA PHARMACEUTICA ... | Drape Eric | Executive VP Global ... | Sell | S | 11.13 | 2,079 | 23,135 | 39,572 | 41.7 K to 39.6 K (-4.99 %) |
Feb 17 2021 | TEVA | TEVA PHARMACEUTICA ... | Drape Eric | Executive VP Global ... | Buy | M | 0.00 | 3,926 | 0 | 41,651 | 37.7 K to 41.7 K (+10.41 %) |
Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Stark David Matthew | Exec. VP Chief Lega ... | Option Exercise | A | 0.00 | 37,884 | 0 | 37,884 | |
Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Stark David Matthew | Exec. VP Chief Lega ... | Option Exercise | M | 0.00 | 12,538 | 0 | 12,538 | |
Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Stark David Matthew | Exec. VP Chief Lega ... | Sell | S | 12.69 | 52,774 | 669,940 | 2,974 | 55.7 K to 3 K (-94.67 %) |
Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Stark David Matthew | Exec. VP Chief Lega ... | Sell | S | 12.69 | 12,538 | 159,164 | 55,748 | 68.3 K to 55.7 K (-18.36 %) |
Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Stark David Matthew | Exec. VP Chief Lega ... | Grant | A | 0.00 | 52,774 | 0 | 68,286 | 15.5 K to 68.3 K (+340.21 %) |
Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Stark David Matthew | Exec. VP Chief Lega ... | Buy | M | 0.00 | 12,538 | 0 | 15,512 | 3 K to 15.5 K (+421.59 %) |
Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Schultz Kare | President and CEO | Option Exercise | M | 0.00 | 26,867 | 0 | 26,867 | |
Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Schultz Kare | President and CEO | Grant | A | 0.00 | 226,173 | 0 | 735,834 | 509.7 K to 735.8 K (+44.38 %) |
Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Schultz Kare | President and CEO | Buy | M | 0.00 | 26,867 | 0 | 509,661 | 482.8 K to 509.7 K (+5.56 %) |
Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Option Exercise | M | 0.00 | 16,120 | 0 | 16,121 | |
Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Sell | S | 12.69 | 16,720 | 212,252 | 78,146 | 94.9 K to 78.1 K (-17.62 %) |
Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Sell | S | 12.69 | 3,974 | 50,448 | 94,866 | 98.8 K to 94.9 K (-4.02 %) |
Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Grant | A | 0.00 | 67,852 | 0 | 98,840 | 31 K to 98.8 K (+218.96 %) |
Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Buy | M | 0.00 | 16,120 | 0 | 30,988 | 14.9 K to 31 K (+108.42 %) |
Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Nazzi Gianfranco | EVP, International ... | Option Exercise | M | 0.00 | 11,941 | 0 | 11,941 | |
Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Nazzi Gianfranco | EVP, International ... | Sell | S | 12.72 | 17,480 | 222,361 | 60,410 | 77.9 K to 60.4 K (-22.44 %) |
Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Nazzi Gianfranco | EVP, International ... | Sell | S | 12.72 | 4,155 | 52,855 | 77,890 | 82 K to 77.9 K (-5.06 %) |
Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Nazzi Gianfranco | EVP, International ... | Grant | A | 0.00 | 50,260 | 0 | 82,045 | 31.8 K to 82 K (+158.12 %) |
Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Nazzi Gianfranco | EVP, International ... | Buy | M | 0.00 | 11,941 | 0 | 31,785 | 19.8 K to 31.8 K (+60.17 %) |
Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Option Exercise | M | 0.00 | 13,135 | 0 | 13,135 | |
Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Sell | S | 12.69 | 23,962 | 304,186 | 59,404 | 83.4 K to 59.4 K (-28.74 %) |
Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Sell | S | 12.69 | 5,695 | 72,295 | 83,366 | 89.1 K to 83.4 K (-6.39 %) |
Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Grant | A | 0.00 | 55,287 | 0 | 89,061 | 33.8 K to 89.1 K (+163.70 %) |
Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Buy | M | 0.00 | 13,135 | 0 | 33,774 | 20.6 K to 33.8 K (+63.64 %) |
Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Option Exercise | M | 0.00 | 13,135 | 0 | 13,135 | |
Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Sell | S | 12.72 | 55,287 | 703,300 | 10,765 | 66.1 K to 10.8 K (-83.70 %) |
Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Sell | S | 12.72 | 13,135 | 167,089 | 66,052 | 79.2 K to 66.1 K (-16.59 %) |
Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Grant | A | 0.00 | 55,287 | 0 | 79,187 | 23.9 K to 79.2 K (+231.33 %) |
Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Buy | M | 0.00 | 13,135 | 0 | 23,900 | 10.8 K to 23.9 K (+122.02 %) |
Nov 03 2020 | TEVA | TEVA PHARMACEUTICA ... | Schultz Kare | President and CEO | Option Exercise | M | 0.00 | 212,314 | 0 | 0 | |
Nov 03 2020 | TEVA | TEVA PHARMACEUTICA ... | Schultz Kare | President and CEO | Option Exercise | M | 0.00 | 180,000 | 0 | 296,389 | |
Nov 03 2020 | TEVA | TEVA PHARMACEUTICA ... | Schultz Kare | President and CEO | Buy | M | 0.00 | 212,314 | 0 | 482,794 | 270.5 K to 482.8 K (+78.50 %) |
Nov 03 2020 | TEVA | TEVA PHARMACEUTICA ... | Schultz Kare | President and CEO | Buy | M | 0.00 | 180,000 | 0 | 270,480 | 90.5 K to 270.5 K (+198.94 %) |
Sep 10 2020 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Option Exercise | M | 0.00 | 698 | 0 | 0 | |
Sep 10 2020 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Sell | S | 8.98 | 333 | 2,992 | 10,765 | 11.1 K to 10.8 K (-3.00 %) |
Sep 10 2020 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Buy | M | 0.00 | 698 | 0 | 11,098 | 10.4 K to 11.1 K (+6.71 %) |
Aug 13 2020 | TEVA | TEVA PHARMACEUTICA ... | Peres Nechemia Jacob | Director | Option Exercise | M | 0.00 | 7,956 | 0 | 0 | |
Aug 13 2020 | TEVA | TEVA PHARMACEUTICA ... | Peres Nechemia Jacob | Director | Buy | M | 0.00 | 7,956 | 0 | 25,577 | 17.6 K to 25.6 K (+45.15 %) |
Aug 13 2020 | TEVA | TEVA PHARMACEUTICA ... | MIGNONE ROBERTO | Director | Option Exercise | M | 0.00 | 7,956 | 0 | 0 | |
Aug 13 2020 | TEVA | TEVA PHARMACEUTICA ... | MIGNONE ROBERTO | Director | Buy | M | 0.00 | 7,956 | 0 | 25,577 | 17.6 K to 25.6 K (+45.15 %) |
Aug 13 2020 | TEVA | TEVA PHARMACEUTICA ... | LIEBERMAN GERALD M | Director | Option Exercise | M | 0.00 | 7,956 | 0 | 0 | |
Aug 13 2020 | TEVA | TEVA PHARMACEUTICA ... | LIEBERMAN GERALD M | Director | Buy | M | 0.00 | 7,956 | 0 | 35,919 | 28 K to 35.9 K (+28.45 %) |
Aug 13 2020 | TEVA | TEVA PHARMACEUTICA ... | Halfon Jean Michel | Director | Option Exercise | M | 0.00 | 7,956 | 0 | 0 | |
Aug 13 2020 | TEVA | TEVA PHARMACEUTICA ... | Halfon Jean Michel | Director | Buy | M | 0.00 | 7,956 | 0 | 30,519 | 22.6 K to 30.5 K (+35.26 %) |
Aug 13 2020 | TEVA | TEVA PHARMACEUTICA ... | Elstein Amir | Director | Option Exercise | M | 0.00 | 7,956 | 0 | 0 | |
Aug 13 2020 | TEVA | TEVA PHARMACEUTICA ... | Elstein Amir | Director | Buy | M | 0.00 | 7,956 | 0 | 2,024,225 | 2 M to 2 M (+0.39 %) |
Aug 13 2020 | TEVA | TEVA PHARMACEUTICA ... | Crane Rosemary A | Director | Option Exercise | M | 0.00 | 7,956 | 0 | 0 | |
Aug 13 2020 | TEVA | TEVA PHARMACEUTICA ... | Crane Rosemary A | Director | Sell | S | 11.90 | 2,860 | 34,038 | 33,509 | 36.4 K to 33.5 K (-7.86 %) |
Aug 13 2020 | TEVA | TEVA PHARMACEUTICA ... | Crane Rosemary A | Director | Buy | M | 0.00 | 7,956 | 0 | 36,369 | 28.4 K to 36.4 K (+28.00 %) |
Aug 13 2020 | TEVA | TEVA PHARMACEUTICA ... | BARER SOL J | Director | Option Exercise | M | 0.00 | 23,133 | 0 | 0 | |
Aug 13 2020 | TEVA | TEVA PHARMACEUTICA ... | BARER SOL J | Director | Buy | M | 0.00 | 23,133 | 0 | 277,433 | 254.3 K to 277.4 K (+9.10 %) |